Technology transfer is another important feature of our HIV/STD research efforts. The laboratory at CPGH performs:
- State of the art diagnostic testing for STDs including microscopy, cultures, ELISAs for HIV, and nucleic acid amplification test (NAAT) based detection of Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis, HPV, and Mycoplasma genitalium.
- Our laboratory supports sophisticated STI testing for Kenyan surveillance programs led by KEMRI and the CDC, as well as STI research projects throughout East Africa
- We have been working with Hologic to develop and deploy their HIV-1 viral load assay for non-subtype B HIV strains. Our laboratory completed training and certification for the viral load assay during the week of October 10th, and we look forward to scaling up our HIV viral load testing in the coming months.
- Monitoring for patients with HIV-1 infection including CD4 cell counts and biochemistry testing required for patients on antiretroviral therapy (ALT, cholesterol, amylase, hemoglobin, glucose, and creatinine).
- We will be screening patients for high-risk HPV sub-types 16 and 18 using Arbor Vita OncoE6 assay on urine and genital specimens as a means of triage to additional cervical screening procedures. We are also validating the use of a novel portable miniature colposcope (Trans Vaginal Digital Colposcope) in screening for cervical lesions.
- We now have capacity for HCV viral load testing at the laboratory in Mombasa, and several research groups around the region are planning grant applications that may make use of this service.